FDA Approves Spravato Nasal Spray for Treatment-Resistant …
4 days ago · WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
SPRAVATO® (esketamine) approved in the U.S. as the first and …
6 days ago · Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1 SPRAVATO® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical ...
FDA approves new nasal spray medication for treatment-resistant ...
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have...
FDA approves Johnson & Johnson nasal spray Spravato for …
6 days ago · Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
FDA allows standalone use of nasal spray antidepressant Spravato ...
5 days ago · The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
FDA approves standalone use of J&J’s ketamine-derived ... - CNN
5 days ago · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...
FDA Approves Spravato Nasal Spray for Treatment-Resistant …
5 days ago · WEDNESDAY, Jan. 22, 2025 -- The U.S. Food and Drug Administration has approved Spravato CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.
SPRAVATO® (esketamine) approved in the U.S. as the first and …
6 days ago · Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray ...
FDA allows standalone use of nasal spray antidepressant Spravato ...
5 days ago · The original approval required that patients on Spravato also receive an oral antidepressant. Now, the FDA says the drug can be used on its own. The decision came after a large study found that Spravato alone worked better than a placebo. In the first nine months of 2024, the drug generated sales of about $780 million for its maker, Johnson ...
FDA approves first-of-its-kind nasal spray for severe depression
5 days ago · Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...
- Some results have been removed